finanzen.net
15.03.2019 19:45
Bewerten
(0)

Osteoarthritis Treatment to 2024: Global Market to be Dominated by Non-steroidal Anti-inflammatory Drugs (NSAIDs)

DRUCKEN

DUBLIN, March 15, 2019 /PRNewswire/ -- The "Osteoarthritis Treatment Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.

The growth of the global osteoarthritis treatment market is due to the rising geriatric population, increasing incidence of osteoarthritis disorders, and rising demand for minimally invasive surgical procedures.

The global increase in geriatric population leads to higher incidence of osteoarthritis (OA) among the aged population. It is the most common type of joint disease, found in people aged more than 65 years, which is accompanied by mortality and decreased quality of life. Osteoarthritis (OA) is one of the most common causes of pain and disability in the elderly population and is driving the growth of the market.

There has also been a rising demand for minimally invasive surgical procedures to treat osteoarthritis, worldwide. MAKOplasty is a minimally invasive knee surgery that relieves the pain caused by osteoarthritis. However, there are also various minimally invasive surgeries that have been reported and are being used nowadays, as they cause less pain and incisions.

In addition, there are many osteoarthritis research studies ongoing on cartilage, the lubricating surface in the joint. The work is being done to re-grow the cartilage using stem cells treated with molecules to aid their growth. Hence, ongoing research and rising government support help in creating new opportunities for the growth of the osteoarthritis treatment market.

Key Market Trends

Non-steroidal Anti-inflammatory Drugs (NSAIDs) is the Largest Segment Under Drugs that is Expected to Grow During the Forecast Period

The NSAIDs market is expected to grow during the forecast period, as they are found to be the most commonly used drugs to ease pain, inflammation, and stiffness that come with arthritis, bursitis, and tendinitis. Thus, NSAIDs have been an important treatment for the symptoms of osteoarthritis for a very long time. They are also cheap and often among the first medicines prescribed for people with achy joints.

The hyaluronic acid injections are also used as a treatment option, when a patient is no longer able to control osteoarthritis pain with ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs).

North America has been reported with the Fastest and the Largest Growth and is Expected to follow the Same Trend over the Forecast Period

The North American market is expected to grow, owing to the increasing lifestyle changes, an increasing number of obesity cases, and an extensive rise in the geriatric population in North America. As a result, the adoption of treatment and drugs is also increasing in the region. The availability of better treatment options, high awareness among people, government reimbursement policies, and the willingness to take up treatment are expected to add up to the growth of the osteoarthritis treatment market in the region.

Competitive Landscape

Various manufacturers are expanding, owing to new product launches in the market. These manufacturers have also seen positive developments in the United States, Europe, Latin America, and Asia. There are also strict regulatory policies, which have resulted in a reduction of investments made by the drug companies in the R&D of new products.

Topics Covered

1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Increasing Incidence of Orthopedic Disorders
4.2.3 Rising Demand for Minimally Invasive Surgical Procedures
4.3 Market Restraints
4.3.1 High Cost Associated with Hyaluronic Acid Products
4.3.2 High Side Effects and Lack of Safety of Products
4.4 Porter's Five Forces Analysis

5 Market Segmentation
5.1 By Drugs
5.1.1 By Food Supplements
5.1.1.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.1.1.2 Corticosteroids
5.1.1.3 Hyaluronic Acid Injection
5.1.1.3.1 Single Injections
5.1.1.3.2 Multiple Injections
5.1.1.4 Other Drugs
5.1.2 By Anatomy
5.1.2.1 Ankle Osteoarthritis
5.1.2.2 Hip Osteoarthritis
5.1.2.3 Knee Osteoarthritis
5.1.2.4 Shoulder Osteoarthritis
5.1.2.5 Other Anatomies
5.2 Geography
5.2.1 North America
5.2.2 Europe
5.2.3 Asia-Pacific
5.2.4 Middle East & Africa
5.2.5 South America

6 Competitive Landscape
6.1 Company Profiles
6.1.1 Bayer Healthcare
6.1.2 Lifecore Biomedical LLC
6.1.3 Merck Serono
6.1.4 Pfizer Consumer Healthcare
6.1.5 Iroko Pharmaceuticals
6.1.6 Sanofi S.A.
6.1.7 Smith & Nephew PLC
6.1.8 Zimmer Biomet

7 Market Opportunities and Future Trends

For more information about this report visit https://www.researchandmarkets.com/research/5jgr8z/osteoarthritis?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/osteoarthritis-treatment-to-2024-global-market-to-be-dominated-by-non-steroidal-anti-inflammatory-drugs-nsaids-300813241.html

SOURCE Research and Markets

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt leichter -- US-Börsen schließen mit Gewinnen -- Levi's mit fulminanter Börsenrückkehr -- FT legt mit Vorwürfen gegen Wirecard nach -- HeidelCement, Fed, Biogen, Siemens, HORNBACH im Foku

Hapag-Lloyd streicht Dividende zusammen. Allianz will HUK Spitzenplatz in der Autoversicherung abjagen. Nemetschek erhöht Dividende und plant Aktiensplit. AXA nimmt mit US-Anteilsverkauf 1,4 Milliarden Dollar ein. Führungsspitze von EssilorLuxottica streitet nach Fusion anscheinend um Chefposten.

Top-Rankings

Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
Die Performance der MDAX-Werte in KW 11 2019.
Welche Aktie macht das Rennen?

Die 5 beliebtesten Top-Rankings

In diesen Ländern ist Netflix am teuersten
Hier müssen Abonnenten tief in die Tasche greifen
Die korruptesten Länder der Welt
In diesen Staaten ist die Korruption am höchsten
Abschlüsse der DAX-Chefs
Diese Studiengänge haben die DAX-Chefs absolviert
Erster Job
Wo Absolventen am meisten Geld verdienen
Das Schwarzbuch 2018/2019
Wo 2018 sinnlos Steuern verbrannt wurden
mehr Top Rankings

Umfrage

Nun ist es bestätigt: Deutsche Bank und Commerzbank loten offiziell eine Fusion aus. Glauben Sie, dass es tatsächlich dazu kommen wird?

finanzen.net Brokerage

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
BayerBAY001
Deutsche Bank AG514000
CommerzbankCBK100
Apple Inc.865985
Amazon906866
Daimler AG710000
Aurora Cannabis IncA12GS7
Deutsche Telekom AG555750
BASFBASF11
SteinhoffA14XB9
NEL ASAA0B733
Allianz840400
TeslaA1CX3T
Volkswagen (VW) AG Vz.766403